CA Patent

CA3021227C — Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection

Assigned to Gilead Sciences Inc · Expires 2020-11-03 · 6y expired

What this patent protects

Compound of formula (Ia), (Ib), (IIa), and (IIb): (see formula Ia) (see formula Ib) (see formula IIa) (see formula IIb) which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus, are provided.

USPTO Abstract

Compound of formula (Ia), (Ib), (IIa), and (IIb): (see formula Ia) (see formula Ib) (see formula IIa) (see formula IIb) which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus, are provided.

Drugs covered by this patent

Patent Metadata

Patent number
CA3021227C
Jurisdiction
CA
Classification
Expires
2020-11-03
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.